International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 2 Mar-Apr 2024, pp: 1648-1662 www.ijprajournal.com ISSN: 2249-7781

"Optimizing Ivermectin Delivery: Advancement in Formulation for Enhanced Efficacy and Safety"

Mr. VaibhavKantilal Chaudhari, Mrs. Sulbha Gopal Patil, Dr. Sunila Atul Patil, Mrs. Amruta Nilesh Patil
Designation:M. Pharm Research Scholar, M. Pharm (Pharmaceutics Department),
Designation: Assistant Professor (Department of Pharmaceutics), P.S.G.V.P. M's College of Pharmacy Shahada (Maharashtra)
Designation: Associate Professor (Department of Pharmaceutical Chemistry), P.S.G.V.P. M's College of Pharmacy Shahada (Maharashtra)
Designation: Assistant Professor (Department of Pharmaceutical Chemistry), P.S.G.V.P. M's College of Pharmacy Shahada (Maharashtra)

Submitted: 12-04-2024 Accepted: 22-04-2024

ABSTRACT:
Ivermectin, a widely used antiparasitic drug, has undergone significant advancements in formulation technologies aimed at enhancing its efficacy and safety across diverse dosage forms. This abstract provides a summary of key findings, implications for clinical practice, and future prospects regarding these advancements. Recent research has focused on developing novel formulations of Ivermectin, including liposomal and Nano-emulsion-based delivery systems. These formulations have demonstrated improved bioavailability, sustained drug release, and enhanced tissue penetration, leading to enhanced therapeutic outcomes with reduced dosing frequency. Additionally, the development of Ivermectin combination therapies with synergistic agents has shown superior efficacy against drug-resistant parasites, offering a promising solution to combat resistance. The implications for clinical practice are significant, with these advancements providing healthcare providers and patients with a wider range of treatment options tailored to individual needs. Sustained-release formulations improve patient compliance and reduce the risk of drug resistance by maintaining therapeutic concentrations over time. Moreover, pediatric-friendly formulations address the challenges of treating parasitic infections in children, ensuring safe and effective therapy. Looking ahead, the future prospects of Ivermectin formulations are promising, driven by ongoing research and technological innovations. Alternative delivery routes such as transdermal, inhalational, and intravitreal administration hold potential for optimizing drug delivery and targeting specific tissues or organs. Integration of pharmacogenomics data and precision medicine strategies may further enhance treatment efficacy while minimizing adverse effects, ushering in a new era of personalized therapeutics.In conclusion, advancements in Ivermectin formulations represent a significant step forward in improving global health outcomes by enhancing the efficacy, safety, and versatility of this essential antiparasitic agent across diverse dosage forms.

I. INTRODUCTION

1.1 Overview of Ivermectin

Ivermectin is a medication belonging to the anthelmintic class of drugs. It is primarily used in the treatment of infections caused by parasites. Parasitic infections that Ivermectin is commonly used to treat include head lice, scabies, river blindness (onchocerciasis), and various types of intestinal worms(1).The mechanism of action of Ivermectin involves its binding to glutamate-gated chloride channels present in the nervous system of parasites. By binding to these channels, Ivermectin causes an influx of chloride ions into the cells of the parasites. This disrupts their normal physiological function, leading to paralysis and eventual death of the parasites(2). Ivermectin can be administered orally in the form of tablets or topically as a cream or lotion, depending on the specific condition being treated. For example, it is often given orally as a single dose for the treatment of certain parasitic infections(3). While Ivermectin is generally considered safe when used as directed for approved indications, it can cause side effects in some individuals. Common side effects include nausea, vomiting, diarrhoea, dizziness, and skin rash. These side effects are usually mild and transient but can be more severe in rare cases(4). During the COVID-19 pandemic, there has been

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 2 Mar-Apr 2024, pp: 1648-1662 www.ijprajournal.com ISSN: 2249-7781

interest in exploring the potential use of Ivermectin for the treatment or prevention of COVID-19. However, conclusive evidence supporting its efficacy for this purpose is lacking, and health authorities such as the FDA and WHO have cautioned against its widespread use for COVID-19 outside of clinical trials(5). There have been reports of parasites developing resistance to Ivermectin, particularly in regions where it is extensively used for mass treatment of diseases such as river blindness. This underscores the importance of using Ivermectin judiciously and in accordance with prescribed guidelines(6).Ivermectin is available by prescription in various formulations, and its use should be overseen by a healthcare professional. It is also used in veterinary medicine for the treatment of parasitic infections in animals(7).

1.2 Background on Ivermectin

Ivermectin was first discovered in the late 1970s by Japanese scientist Dr. Satoshi Ōmura, who isolated it from the soil-dwelling bacterium Streptomyces avermitilis. Dr. Ōmura's work was part of a larger project aimed at screening soil samples for potentially beneficial microorganisms. He found that extracts from S. avermitilis showed potent activity against parasitic nematodes in laboratory tests. In 1978, Dr. Ōmura shared his findings with Dr. William Campbell, an Irish parasitologist working at the pharmaceutical company Merck & Co. Dr. Campbell and his team then isolated and purified the active compound from the microbial extracts, naming it "Ivermectin."(1). Merck & Co. recognized the significant potential of Ivermectin as an anthelmintic (anti-parasitic) agent and began conducting further research and development. Clinical trials followed, demonstrating the efficacy of Ivermectin in treating a variety of parasitic infections in humans and animals(8). In 1981, Merck & Co. obtained FDA approval for ivermectin's use in veterinary medicine, particularly for the treatment of parasites in livestock. Subsequently, in 1987, the FDA approved Ivermectin for human use, initially for the treatment of onchocerciasis (river blindness), a debilitating parasitic disease prevalent in many tropical regions(9).Ivermectin's efficacy, safety, and ease of administration made it a cornerstone of efforts to combat various parasitic diseases worldwide. It played a crucial role in large-scale public health campaigns aimed at eliminating diseases such as lymphatic filariasis (elephantiasis) and soil-transmitted helminthiasis (intestinal worm infections)(10).Over the years, ivermectin's use expanded to include the treatment of other parasitic conditions, such as scabies and head lice, further solidifying its status as a vital tool in global health initiatives.In recent years, Ivermectin has garnered attention for its potential off-label uses, including the treatment of certain viral infections and as a possible therapeutic option for COVID-19. However, its effectiveness for these purposes remains subject to ongoing research and debate, with health authorities urging caution and adherence to established clinical guidelines(10).

1.3 Importance of Ivermectin in healthcare

Ivermectin holds significant importance in healthcare for several reasons:

1.Treatment of Parasitic Infections:

Ivermectin is highly effective in treating a wide range of parasitic infections in humans and animals. These include river blindness (onchocerciasis), lymphatic filariasis (elephantiasis), strongyloidiasis, scabies, head lice, and various types of intestinal worms. Its efficacy in treating these infections has made it a cornerstone of public health efforts to control and eliminate parasitic diseases globally(10).

2. Global Health Impact:

Ivermectin has had a transformative impact on global health by helping to control and eliminate neglected tropical diseases (NTDs). Through mass drug administration campaigns, particularly in regions where parasitic diseases are endemic, Ivermectin has played a crucial role in reducing the burden of these diseases and improving the quality of life for millions of people, especially in low- and middle-income countries(11).

3. Safety and Accessibility:

Ivermectin is generally well-tolerated and has a favourable safety profile when used as directed. Its ease of administration, often as a single oral dose, makes it particularly suitable for mass treatment programs in resource-limited settings. Additionally, Ivermectin is available in various formulations, including tablets, creams, and lotions, making it accessible for different patient populations(12)

4. Veterinary Medicine:

In addition to its human health applications, Ivermectin is widely used in veterinary medicine for the treatment and prevention of parasitic infections in livestock and

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 2 Mar-Apr 2024, pp: 1648-1662 www.ijprajournal.com ISSN: 2249-7781

companion animals. Its effectiveness and safety in animals contribute to maintaining animal health and welfare, as well as ensuring the safety of food supplies by controlling parasites in livestock(8).

5. Research and Development:

Ivermectin's discovery and subsequent development highlight the potential of natural products and microbial-derived compounds as sources of new drugs. The success of Ivermectin has inspired further research into similar compounds and mechanisms of action, leading to the discovery of other important medications(9).

6. Potential Therapeutic Applications:

While the primary indications for Ivermectin are for parasitic infections, there is ongoing research into its potential therapeutic applications for other conditions, including certain viral infections and inflammatory diseases. While further studies are needed to establish its efficacy for these purposes, its potential broad-spectrum antiviral activity has generated considerable interest, particularly during public health crises such as the COVID-19 pandemic(10).

1.4. Need for advancements in Ivermectin formulations:

1.4.1. Improved Patient Compliance:

Many parasitic infections treated with Ivermectin require multiple doses over several days or weeks. Developing long-acting formulations that require less frequent dosing could improve patient compliance, particularly in resource-limited settings where access to healthcare services may be limited(13).

1.4.2. Enhanced Stability and Shelf Life:

Current formulations of Ivermectin may have stability issues, especially in tropical climates where parasitic infections are prevalent. Formulations that offer improved stability and longer shelf life would ensure the availability of effective treatment options even in challenging environmental conditions(14).

1.4.3. Alternative Routes of Administration:

While oral administration is the most common route for Ivermectin, alternative routes such as topical, subcutaneous, or intramuscular administration could offer advantages in specific situations. For example, topical formulations may be preferred for treating skin conditions like scabies, while injectable formulations could be useful in veterinary medicine or for specific patient populations(15).

1.4.4. Targeted Delivery Systems:

Developing targeted delivery systems could improve the efficacy of Ivermectin while minimizing side effects. For example, nanoparticles or liposomes could be used to deliver Ivermectin directly to the site of infection, reducing systemic exposure and enhancing therapeutic outcomes(16).

1.4.5. Combination Therapies:

Combining Ivermectin with other drugs or therapeutic agents could improve treatment outcomes, especially in cases of drug-resistant parasites or complex infections. Formulating Ivermectin in combination with other anthelmintic or anti-parasitic drugs could provide synergistic effects and reduce the risk of resistance development(17).

1.4.6. Paediatric Formulations:

Developing formulations specifically tailored for paediatric patients, such as flavoured syrups or chewable tablets, could improve the acceptability and palatability of Ivermectin in children, leading to better treatment adherence and outcomes(18).

1.4.7. Cost-effective Formulations:

In many low- and middle-income countries, cost is a significant barrier to accessing essential medications like Ivermectin. Developing cost-effective formulations that maintain efficacy while reducing production costs could improve access to treatment for underserved populations(19).

1.4.8. Sustainable Production Methods:

As the demand for Ivermectin continues to grow, there is a need for sustainable production methods that minimize environmental impact and ensure a stable supply of the drug. Developing environmentally friendly manufacturing processes and sourcing raw materials responsibly are essential considerations for future advancements in Ivermectin formulations(20).

Overall, advancements in Ivermectin formulations are essential for improving treatment outcomes, enhancing patient compliance, expanding access to care, and addressing emerging challenges such as drug resistance and environmental sustainability. Collaborative efforts between pharmaceutical companies, researchers, healthcare providers, and policymakers are needed

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 2 Mar-Apr 2024, pp: 1648-1662 www.ijprajournal.com ISSN: 2249-7781

to drive innovation in this critical area of global health(21).

II. TRADITIONAL IVERMECTIN FORMULATIONS

2.1 Oral tablets

2.1.1. Dosage and administration

The dosage of Ivermectin can vary depending on the specific parasitic infection being treated, as well as factors such as the patient's age, weight, and medical history. It is crucial to follow the prescribing healthcare professional's instructions carefully(10).

The standard dosages for some common parasitic infections are as follows: Onchocerciasis (river blindness): A single oral dose of 150 to 200 micrograms per kilogram of body weight (µg/kg). This may be repeated every 6 to 12 months, depending on the severity of the infection(22)

Strongyloidiasis: A single oral dose of 200 micrograms per kilogram of body weight (µg/kg), given as a one-time treatment(23).

Scabies: A single oral dose of 200 micrograms per kilogram of body weight (µg/kg), repeated(24) after 2 weeks if necessary.

Head lice: The dosage and regimen may vary. Typically, a single oral dose is administered, followed by a second dose after 7 to 14 days(24).

Oral tablets of Ivermectin are usually taken with water on an empty stomach. Food can affect the absorption of the medication, so it's often recommended to take it at least one hour before or two hours after a meal.Depending on the specific indication, a single dose of Ivermectin may be sufficient to treat the infection effectively. However, in some cases, particularly with certain parasitic infections like onchocerciasis, repeated doses may be necessary at regular intervals to ensure complete eradication of the parasites and prevent recurrence(25).

Follow-up: After treatment with Ivermectin, it's essential for patients to follow up with their healthcare provider for monitoring and assessment of treatment efficacy. In some cases, additional tests or examinations may be required to confirm eradication of the parasites and ensure the patient's overall health(26).It's important for patients to adhere to the prescribed dosage and administration instructions and to consult their healthcare provider if they have any questions or concerns about their treatment with Ivermectin. Additionally, healthcare providers should consider factors such as drug interactions and potential side effects when prescribing Ivermectin to patients(27).

Efficacy and safety profile:

Parasitic Infections: Ivermectin is highly effective in treating a wide range of parasitic infections in humans and animals. It has demonstrated efficacy against conditions such as onchocerciasis (river blindness), lymphatic filariasis (elephantiasis), strongyloidiasis, scabies, head lice, and various types of intestinal worms. In many cases, a single dose of Ivermectin is sufficient to achieve cure or significant reduction in parasite burden(1).

Global Health Impact: Ivermectin has played a crucial role in global health initiatives aimed at controlling and eliminating neglected tropical diseases (NTDs). Mass drug administration programs with Ivermectin have led to significant reductions in the prevalence and transmission of parasitic infections, thereby improving the health and well-being of affected populations worldwide(28).

Safety Profile:Generally Well-Tolerated: Ivermectin is generally well-tolerated when used as directed. Most adverse effects are mild and transient.

Common Side Effects: Common side effects of Ivermectin include nausea, vomiting, diarrhoea, dizziness, and skin rash. These side effects typically occur shortly after administration and resolve on their own without requiring medical intervention(28).

Rare Side Effects: In rare cases, particularly with high doses or prolonged use, more serious side effects may occur. These can include neurotoxicity, allergic reactions (such as itching, hives, or swelling), and potentially severe skin reactions(29).

Drug Interactions: Ivermectin may interact with other medications, especially those that affect liver enzymes involved in drug metabolism. Patients should inform their healthcare providers about all medications, supplements, and herbal remedies they are taking before starting Ivermectin therapy to minimize the risk of interactions(30)

Special Populations: Special caution is warranted when administering Ivermectin to certain populations, such as pregnant or breastfeeding women, children, and individuals with liver or kidney dysfunction. Dosage adjustments may be necessary in these cases to minimize the risk of adverse effects(31).

During the COVID-19 pandemic, there has been interest in repurposing Ivermectin for the treatment or prevention of COVID-19. However, the evidence supporting its efficacy for this purpose

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 2 Mar-Apr 2024, pp: 1648-1662 www.ijprajournal.com ISSN: 2249-7781

remains inconclusive, and health authorities have cautioned against its widespread use for COVID-19 outside of clinical trials. Patients should not self-medicate with Ivermectin for COVID-19 without consulting a healthcare professional(7).

2.2 Topical formulations

Creams: Creams are semi-solid emulsions that contain a combination of water and oil. They are easy to apply and spread evenly over the skin. Ivermectin cream is commonly used for the treatment of conditions such as rosacea. Rosacea is a chronic inflammatory skin condition that primarily affects the face, causing redness, flushing, and sometimes small, pus-filled bumps. Ivermectin cream has anti-inflammatory and anti-parasitic properties that can help alleviate the symptoms associated with rosacea by reducing inflammation and targeting the Demodex mites believed to contribute to the condition(32).

Lotions: Lotions are liquid preparations that are easy to spread over the skin. They typically contain a higher proportion of water compared to creams, making them lighter in texture. Ivermectin lotion is commonly used for the treatment of scabies, a highly contagious skin infestation caused by the Sarcoptesscabiei mite. Scabies manifests as intense itching and a rash, particularly in areas where the mites have burrowed into the skin. Ivermectin lotion works by killing the mites and their eggs, thereby eliminating the infestation and relieving symptoms(32).

Gels: Gels are semi-solid preparations that are similar to creams but have a more jelly-like consistency. They are often preferred for their cooling and soothing properties. While topical gels containing Ivermectin may not be as common as creams and lotions, they can still be used for targeted application to affected areas of the skin. The gel formulation can be particularly useful for conditions such as rosacea, where precise application to areas of inflammation is desired(33).

Overall, topical formulations of Ivermectin offer a convenient and effective way to deliver the medication directly to the skin, where it can act locally to treat various parasitic skin conditions. However, it's essential to use these formulations as directed by a healthcare professional to ensure safe and effective treatment. Additionally, it's important to be aware of any potential side effects or contraindications associated with the use of Ivermectin, and to consult a healthcare provider if you have any concerns(34).

2.2.1. Uses:

1. Scabies Treatment: One of the primary use cases for topical Ivermectin formulations is the treatment of scabies. Scabies is a highly contagious skin infestation caused by the Sarcoptesscabiei mite. Topical application of Ivermectin in the form of lotions can effectively kill the mites and their eggs, providing relief from itching and eliminating the infestation(35).

2. Rosacea Management: Topical Ivermectin creams are commonly used for the management of rosacea, a chronic inflammatory skin condition. Rosacea is characterized by redness, flushing, and sometimes pustules on the face. Ivermectin cream can help reduce inflammation and target Demodex mites, which are believed to play a role in the development of rosacea, thereby improving symptoms and appearance(36).

3.Other Parasitic Skin Infections: In addition to scabies and rosacea, topical Ivermectin formulations may also be used for the treatment of other parasitic skin infections, such as certain types of mite infestations or ectoparasitic infections(34).

2.2.2. Limitations:

Limited Efficacy: While topical formulations of Ivermectin can be effective for certain skin conditions, their efficacy may vary depending on the severity of the condition and individual factors. In some cases, oral administration of Ivermectin or other treatment modalities may be more effective(37).

Resistance Development: There is concern about the development of resistance to Ivermectin, both in parasites and in the bacteria associated with conditions like rosacea. Prolonged or repeated use of topical Ivermectin may contribute to the development of resistance, potentially reducing its effectiveness over time(3).

Side Effects: Like any medication, topical Ivermectin formulations can cause side effects in some individuals. Common side effects may include skin irritation, itching, redness, or burning sensation at the application site. In rare cases, more serious side effects such as allergic reactions or worsening of underlying skin conditions may occur(35).

Not Suitable for All Skin Condition: While topical Ivermectin may be effective for certain parasitic skin conditions, it may not be suitable for all types of skin conditions. It's essential to consult a healthcare professional for an accurate diagnosis and appropriate treatment plan tailored to individual needs.

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 2 Mar-Apr 2024, pp: 1648-1662 www.ijprajournal.com ISSN: 2249-7781

Cost and Availability: Topical formulations of Ivermectin may not be readily available in all regions, and cost can be a limiting factor for some patients. Additionally, insurance coverage for these formulations may vary, making them inaccessible to some individuals(34).

III. ADVANCEMENTS IN IVERMECTIN FORMULATIONS

3.2 Nanoparticle-based formulations

Advancements in Ivermectin formulations have been ongoing, with researchers exploring various approaches to enhance efficacy, bioavailability, and targeted delivery. One such advancement involves nanoparticle-based formulations of Ivermectin(16).

Nanoparticle-Based Formulations of Ivermectin:

1.Improved Bioavailability: Nanoparticle-based formulations can enhance the bioavailability of Ivermectin, allowing for better absorption and distribution within the body. By encapsulating Ivermectin within nanoparticles, researchers can overcome challenges related to its poor solubility and stability, leading to improved pharmacokinetics(38).

2. Targeted Delivery: Nanoparticles can be engineered to target specific tissues or cells, enabling localized delivery of Ivermectin to the site of infection or inflammation. This targeted approach minimizes systemic exposure and reduces the risk of adverse effects associated with conventional formulations(39).

3. Sustained Release: Nanoparticle-based formulations can provide sustained release of Ivermectin over an extended period, prolonging its therapeutic effect and reducing the frequency of dosing. This is particularly beneficial for chronic conditions requiring long-term treatment, such as certain parasitic infections or inflammatory skin disorders.

4. Enhanced Stability: Nanoparticles can protect Ivermectin from degradation and improve its stability, ensuring consistent drug concentrations and efficacy over time. This is especially important for formulations intended for storage or transportation in challenging environmental conditions(40).

5. Combination Therapy: Nanoparticle-based formulations allow for the co-delivery of Ivermectin with other therapeutic agents, such as antimicrobial agents or immunomodulatory, to enhance treatment outcomes. By incorporating multiple drugs into a single nanoparticle system, researchers can synergize their effects and combat complex infections or diseases more effectively.

6.Potential for Novel Administration Routes: Nanoparticle-based formulations of Ivermectin may enable novel administration routes, such as inhalation or transdermal delivery. These alternative routes offer advantages such as improved patient compliance, reduced systemic exposure, and targeted delivery to specific anatomical sites(41).

Enhanced Bioavailability:

Nanoparticle-based formulations of Ivermectin offer enhanced bioavailability through three main mechanisms:

1. Improved Solubility: Encapsulation within nanoparticles increases ivermectin's solubility and dissolution rate, facilitating better absorption across biological barriers, leading to increased bioavailability.
2. Protection from Degradation: Nanoparticles act as protective carriers, shielding Ivermectin from enzymatic degradation and metabolic processes, thereby enhancing its stability in biological fluids and prolonging circulation time for improved bioavailability.
3. Facilitated Transport: Nanoparticles optimize cellular uptake and intracellular delivery of Ivermectin through manipulation of particle characteristics, such as size, surface charge, and surface modifications, enhancing bioavailability by facilitating transport across biological membranes(38).

Enhanced Efficacy:

1. Targeted Delivery: Nanoparticles deliver Ivermectin precisely to the intended site of action, maximizing drug concentration while minimizing off-target effects and systemic toxicity.
2. Sustained Release: These formulations provide prolonged exposure of parasites or affected tissues to Ivermectin, ensuring continuous therapeutic drug levels and maximizing efficacy over time.
3. Combination Therapy: Nanoparticles enable co-delivery of Ivermectin with other therapeutic agents, allowing for synergistic combinations that enhance treatment efficacy against various infections or inflammatory conditions by addressing multiple pathological pathways simultaneously.

Overall, nanoparticle-based formulations overcome limitations of conventional formulations, offering promising strategies for improving therapeutic outcomes in a range of conditions

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 2 Mar-Apr 2024, pp: 1648-1662 www.ijprajournal.com ISSN: 2249-7781

where Ivermectin has shown efficacy. Further research and development are expected to optimize these delivery systems for clinical use(42).

Research and clinical trials

Research and clinical trials play a pivotal role in advancing nanoparticle-based formulations of Ivermectin, encompassing various stages:

Formulation Development: Optimization of nanoparticle carriers for enhanced drug loading and targeted delivery.

In vitro Studies: Evaluation of cellular uptake, intracellular trafficking, and cytotoxicity.

In vivo Pharmacokinetics: Assessment of biodistribution, tissue penetration, and systemic exposure in animal models(43).

Parasitic Infections: Clinical trials evaluate efficacy in onchocerciasis, lymphatic filariasis, etc.

Inflammatory Skin Conditions: Assessment in conditions like rosacea and demodicosis(44).

Toxicology Studies: Evaluation of biocompatibility, systemic toxicity, and adverse effects.

Clinical Safety Trials: Monitoring adverse events and safety endpoints in human subjects(45).

Regulatory Submissions: Submission of comprehensive data for approval by regulatory authorities.

Post-Marketing Surveillance: Monitoring safety and effectiveness post-approval(46).

3.2 Liposomal formulations

Structure: Liposomes are spherical vesicles composed of lipid bilayers, encapsulating hydrophobic drugs like Ivermectin within their lipid bilayers or aqueous cores.

Drug Encapsulation: Various methods are employed to encapsulate Ivermectin within liposomes, enhancing its solubility, stability, and bioavailability.

Surface Modifications: Liposomes can be surface-modified with targeting ligands for specific delivery to target tissues or cells, minimizing off-target effects.

Sustained Release: Liposomes provide sustained release of Ivermectin, ensuring continuous therapeutic effect and reducing dosing frequency(47).

Potential Applications:

Parasitic Infections: Liposomal Ivermectin shows efficacy in treating parasitic infections, improving clearance rates and reducing disease burden.

Inflammatory Skin Conditions: It can be beneficial for managing inflammatory skin conditions by reducing inflammation and suppressing Demodex mite proliferation.

Vector-Borne Diseases: Liposomal Ivermectin may help prevent and control vector-borne diseases by targeted delivery to vector tissues, disrupting transmission cycles(48).

Drug Resistance Management: Liposomal formulations can help overcome drug resistance mechanisms, improving treatment outcomes in resistant infections.

Preclinical Studies: Focus on formulation optimization and efficacy assessment in animal models of parasitic infections and inflammatory diseases.

Clinical Trials: Conducted to evaluate safety, efficacy, and pharmacokinetics in human subjects.

Regulatory Approval: Regulatory submissions based on comprehensive data for commercialization and clinical use(49).

Improved drug delivery and tissue targeting

Improved Solubility: Liposomes increase ivermectin's solubility in biological fluids, enhancing its absorption and distribution, thus improving bioavailability and efficacy.

Protection from Degradation: Liposomes shield Ivermectin from enzymatic degradation and metabolic processes, maintaining its stability and prolonging circulation time(50).

1. Passive Targeting: Liposomes accumulate in areas of inflammation or tumour growth via the enhanced permeability and retention (EPR) effect, increasing drug concentration at the target site.

2. Active Targeting: Surface-modified liposomes deliver Ivermectin selectively to diseased tissues or cells, minimizing off-target effects on healthy tissues(51).

1. Sustained Release: Liposomal formulations provide prolonged drug action and reduced dosing frequency by ensuring continuous delivery to the target site.

2. Site-Specific Accumulation: Liposomes can be tailored to accumulate selectively in specific tissues or organs associated with parasitic infections or inflammatory conditions(52).

Minimized Systemic Toxicity:

1. Reduced Systemic Exposure: Liposomes minimize off-target effects by enhancing drug accumulation at the target site while reducing distribution to non-target tissues, thus mitigating systemic toxicity(53).

2. Localized Therapy: Liposomal formulations deliver Ivermectin directly to the site of infection or

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 2 Mar-Apr 2024, pp: 1648-1662 www.ijprajournal.com ISSN: 2249-7781

inflammation, reducing exposure to healthy tissues and improving the safety profile of the treatment(54).

Research and Development:

1.Formulation Optimization: Ongoing efforts focus on fine-tuning liposomal formulations to maximize drug delivery and tissue targeting while minimizing adverse effects.

2. Preclinical Evaluation: Studies assess the pharmacokinetics, biodistribution, and efficacy of liposomal Ivermectin in relevant animal models.

3. Clinical Translation: Clinical trials aim to validate the therapeutic potential of liposomal Ivermectin and pave the way for its clinical use in various diseases(55).

Comparative studies with traditional formulations

Comparative studies between liposomal formulations of Ivermectin and traditional formulations provide valuable insights into various aspects:

Bioavailability: Assessing Ivermectin concentration in blood plasma or tissues after administration via different routes.

Distribution: Examining the extent and pattern of drug distribution within the body.

Parasite Clearance: Evaluating the ability to clear parasitic infections.

Disease Control: Comparing efficacy in managing inflammatory skin conditions(56).

Systemic Toxicity: Monitoring adverse events and organ function tests.

Local Irritation: Assessing incidence and severity of local irritation for topical formulations(57).

Mechanism of Action: Investigating effects on parasites or inflammatory pathways.

Duration of Action: Comparing sustained therapeutic effects(58).

Ease of Administration: Evaluating ease and convenience of treatment.

Treatment Satisfaction: Measuring adherence rates and quality of life improvements(59).

3.3 Injectable formulations

Injectable formulations of Ivermectin, including long-acting injectables, offer unique advantages in terms of pharmacokinetics and therapeutic benefits.

Long-Acting Injectable Formulations:

1.Extended Release: Long-acting injectable formulations of Ivermectin are designed to provide sustained release of the drug over an extended period, ranging from weeks to months. These formulations typically involve encapsulating Ivermectin in biodegradable or sustained-release delivery systems, such as polymer microspheres or lipid nanoparticles(60).

2. Single Dose Administration: Long-acting injectables allow for a single dose administration, providing convenience for patients and healthcare providers compared to frequent dosing regimens required with conventional oral or topical formulations. This can improve treatment adherence and reduce the risk of treatment interruption or non-compliance(61).

3. Stable Plasma Levels: Long-acting injectables maintain stable plasma levels of Ivermectin over an extended duration, minimizing fluctuations in drug concentration and ensuring continuous therapeutic effect. This sustained drug release profile optimizes treatment efficacy and reduces the likelihood of breakthrough infections or disease recurrence(62).

4.Reduced Dosing Frequency: Compared to short-acting injectables or oral formulations, long-acting injectables require less frequent dosing, leading to improved patient compliance and treatment outcomes. This is particularly advantageous for chronic conditions requiring long-term therapy, where regular dosing can be burdensome for patients(63).

Pharmacokinetic Advantages:

1. Prolonged Half-Life: Extended duration of action due to sustained drug exposure, allowing for less frequent dosing intervals(64).

2. Improved Tissue Penetration: Enhanced distribution to deep tissues or organs, bypassing first-pass metabolism and gastrointestinal absorption(65).

3. Targeted Delivery: Localized delivery to specific tissues or cells, minimizing systemic exposure and off-target effects(21).

4. Extended Duration of Protection: Continuous disease control with reduced need for frequent re-administration, beneficial for chronic conditions or disease prevention(66).

Clinical Applications:

1. Parasitic Infections: Treatment and prevention of parasitic infections, ensuring sustained parasite clearance and disease control, particularly in endemic regions(67).

2. Vector Control: Strategies to reduce transmission of vector-borne diseases, targeting insect vectors and providing sustained protection in high-risk communities(68).

3. Inflammatory Disorders: Therapeutic benefits for inflammatory conditions, offering sustained

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 2 Mar-Apr 2024, pp: 1648-1662 www.ijprajournal.com ISSN: 2249-7781

anti-inflammatory effects and symptom improvement over time(69).

IV. COMPARATIVE ANALYSIS OF DIFFERENT DOSAGE FORMS

1. Efficacy of Oral Formulations: Oral formulations of Ivermectin, like tablets or solutions, have shown high efficacy in treating various parasitic infections such as onchocerciasis, lymphatic filariasis, and intestinal helminthiasis. Oral administration enables systemic distribution of Ivermectin, effectively targeting parasites throughout the body(67).

2. Efficacy of Topical Formulations: Topical formulations of Ivermectin, including creams or lotions, are primarily used to treat localized skin conditions like scabies and rosacea. These formulations deliver Ivermectin directly to the affected area, providing targeted action against parasites or inflammatory processes in the skin(3).

3. Efficacy of Injectable Formulations: Injectable formulations of Ivermectin, including long-acting injectables, offer sustained release and prolonged duration of action. They are effective in treating systemic parasitic infections and may also aid in vector control efforts in endemic regions(70).

Safety Profile:

1. Safety of Oral Formulations: Oral Ivermectin is generally well-tolerated, with mild and transient side effects such as gastrointestinal upset, dizziness, and headache being common. Serious adverse effects like neurotoxicity or allergic reactions are rare but can occur, especially at high doses(35).

2. Safety of Topical Formulations: Topical Ivermectin formulations are safe for local application, with minimal systemic absorption and low risk of systemic side effects. Local skin reactions such as erythema or pruritus may occur but are usually mild and resolve with continued use(71).

3. Safety of Injectable Formulations: Injectable Ivermectin formulations, including long-acting injectables, require careful administration to minimize the risk of injection site reactions or systemic toxicity. Adverse effects like pain or swelling at the injection site, allergic reactions, or neurotoxicity may occur, particularly with high doses or repeated administration(72).

Patient Compliance and Convenience:

1. Compliance with Oral Formulations: Oral Ivermectin offers ease of administration and is suitable for self-administration, improving patient compliance. However, multiple doses may be necessary for certain infections, affecting treatment adherence, especially in resource-limited settings(73).

2. Convenience of Topical Formulations: Topical Ivermectin formulations are convenient for localized skin conditions, as they can be applied directly to the affected area. However, frequent application may be required, and adherence to the treatment regimen can be challenging, especially for extensive or hard-to-reach areas of the body(40).

3. Convenience of Injectable Formulations: Injectable Ivermectin formulations, particularly long-acting injectables, offer the convenience of a single-dose administration, reducing the need for frequent dosing and improving treatment adherence. However, they require healthcare provider administration, which may limit accessibility in certain settings(60).

V. CLINICAL APPLICATIONS AND THERAPEUTIC USES

A. Treatment of Parasitic Infections:

1. Onchocerciasis (River Blindness): Ivermectin is highly effective in treating onchocerciasis, a parasitic infection caused by the filarial worm Onchocerca volvulus. Mass drug administration (MDA) programs have successfully controlled and eliminated onchocerciasis in endemic regions by distributing Ivermectin to at-risk populations(11).

2.Lymphatic Filariasis: Ivermectin, often in combination with albendazole or diethylcarbamazine, is used to treat lymphatic filariasis, a parasitic infection caused by Wuchereriabancrofti, Brugiamalayi, or Brugiatimori. MDA programs aim to interrupt transmission and eliminate lymphatic filariasis in endemic areas(74).

3. Scabies: Ivermectin is effective in treating scabies, a contagious skin infestation caused by the mite Sarcoptesscabiei. Oral or topical formulations of Ivermectin are used to eradicate scabies infestations, particularly in cases of resistance or widespread outbreaks(75).

4. Soil-Transmitted Helminthiasis: Ivermectin is used as part of deworming programs to control soil-transmitted helminth infections, including roundworm (Ascarislumbricoides), whipworm (Trichuristrichiura), and hookworm

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 2 Mar-Apr 2024, pp: 1648-1662 www.ijprajournal.com ISSN: 2249-7781

(Necatoramericanus and Ancylostomaduodenale) (76).

B. Potential in Treating Viral Infections (e.g., COVID-19):

1.Antiviral Activity: Some studies suggest that Ivermectin may have antiviral properties against certain viruses, including SARS-CoV-2, the virus responsible for COVID-19. In vitro studies have demonstrated potential inhibition of viral replication, although clinical evidence is still emerging(77).

2.Clinical Trials for COVID-19: Clinical trials are underway to evaluate the efficacy and safety of Ivermectin in treating COVID-19. Preliminary results from some studies suggest potential benefits in reducing viral load, improving clinical outcomes, and reducing mortality rates, but further research is needed to confirm these findings(78).

C. Other Emerging Applications:

1. Vector Control: Ivermectin has been explored for its potential in vector control strategies to reduce transmission of vector-borne diseases, such as malaria, dengue fever, and Zika virus. Mass administration of Ivermectin to human populations or livestock can target insect vectors, such as mosquitoes, and reduce their lifespan or ability to transmit pathogens(79).

2. Inflammatory Skin Conditions: Emerging research suggests that Ivermectin may have anti-inflammatory properties and could be beneficial in the treatment of inflammatory skin conditions, such as rosacea and demodicosis. Topical formulations of Ivermectin have shown efficacy in reducing inflammation and controlling symptoms associated with these conditions(36).

3. Cancer: Preclinical studies have investigated the potential anticancer effects of ivermectin, including inhibition of tumor cell proliferation, induction of apoptosis, and modulation of cancer-associated signalling pathways. However, further research is needed to elucidate its therapeutic potential and safety profile in cancer treatment(80).

VI. CONCLUSION:

In conclusion, the advancements in Ivermectin formulations represent a significant stride towards enhancing the efficacy and safety of this widely used anti-parasitic drug across diverse dosage forms. Through a comprehensive review of key findings, implications for clinical practice, and future prospects, it becomes evident that ongoing research and innovation continue to refine and optimize the therapeutic potential of Ivermectin. One of the key findings from recent studies is the effectiveness of novel formulations such as liposomal and Nano emulsion-based delivery systems. These formulations have shown improved bioavailability, prolonged drug release, and enhanced tissue penetration, leading to better treatment outcomes with reduced dosing frequency. Additionally, the development of Ivermectin combination therapies with synergistic agents has demonstrated superior efficacy against resistant parasites, paving the way for more targeted and effective treatments.

The implications for clinical practice are profound, with these advancements offering healthcare providers and patients a broader range of treatment options tailored to individual needs. The availability of sustained-release formulations not only improves patient compliance but also reduces the risk of drug resistance by maintaining therapeutic concentrations over an extended period. Moreover, the development of paediatric-friendly formulations addresses the specific challenges of treating parasitic infections in children, ensuring safe and effective therapy for this vulnerable population.Looking ahead, the future prospects of Ivermectin formulations are promising, driven by ongoing research initiatives and technological advancements. The exploration of alternative delivery routes such as transdermal, inhalational, and intravitreal administration opens up new avenues for optimizing drug delivery and targeting specific tissues or organs. This personalized approach holds great potential for addressing the challenges posed by drug-resistant parasites and emerging infectious diseases. Furthermore, the integration of pharmacogenomics data and precision medicine strategies may facilitate the development of individualized treatment regimens based on patient-specific factors such as genetic polymorphisms and drug metabolism profiles. This paradigm shift towards precision therapeutics not only enhances treatment efficacy but also minimizes adverse effects and promotes overall patient safety.

In addition to its antiparasitic properties, recent studies have highlighted the potential immunomodulatory and antiviral effects of Ivermectin, particularly in the context of viral infections such as COVID-19. While further research is needed to elucidate the underlying mechanisms and clinical benefits, the versatility of Ivermectin as a multi-faceted therapeutic agent underscores its relevance in addressing a wide spectrum of infectious diseases. In conclusion, the continuous evolution of Ivermectin formulations

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 2 Mar-Apr 2024, pp: 1648-1662 www.ijprajournal.com ISSN: 2249-7781

represents a testament to scientific innovation and collaborative efforts aimed at improving global health outcomes. By harnessing the full potential of advanced drug delivery systems, personalized medicine approaches, and interdisciplinary research endeavours, we can unlock new frontiers in the fight against parasitic infections and other global health challenges.

REFERENCE:

[1]. CRUMP A, ŌMURA S. Ivermectin, 'Wonder drug' from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci. 2011 Feb 10;87(2):13–28.

[2]. Atif M, Estrada-Mondragon A, Nguyen B, Lynch JW, Keramidas A. Effects of glutamate and ivermectin on single glutamate-gated chloride channels of the parasitic nematode H. contortus. PLoS Pathog. 2017 Oct 2;13(10):e1006663.

[3]. Mathachan SR, Sardana K, Khurana A. Current Use of Ivermectin in Dermatology, Tropical Medicine, and COVID-19: An Update on Pharmacology, Uses, Proven and Varied Proposed Mechanistic Action. Indian Dermatol Online J. 2021 Aug;12(4):500.

[4]. Shirazi FM, Mirzaei R, Nakhaee S, Nejatian A, Ghafari S, Mehrpour O. Repurposing the drug, ivermectin, in COVID-19: toxicological points of view. Eur J Med Res. 2022 Feb 5;27:21.

[5]. Onyeaka H, Tamasiga P, Agbara JO, Mokgwathi OA, Uwishema O. The use of Ivermectin for the treatment of COVID-19: Panacea or enigma? Clin Epidemiol Glob Health. 2022;16:101074.

[6]. Cupp EW, Mackenzie CD, Unnasch TR. Importance of ivermectin to human onchocerciasis: past, present, and the future. Res Rep Trop Med. 2011 May 30;2:81–92.

[7]. Popp M, Reis S, Schießer S, Hausinger RI, Stegemann M, Metzendorf MI, et al. Ivermectin for preventing and treating COVID- 19. Cochrane Database Syst Rev. 2022 Jun 21;2022(6):CD015017.

[8]. Sulik M, Antoszczak M, Huczyński A, Steverding D. Antiparasitic activity of ivermectin: Four decades of research into a "wonder drug." Eur J Med Chem. 2023 Dec 5;261:115838.

[9]. Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations | The Journal of Antibiotics [Internet]. [cited 2024 Apr 8]. Available from: https://www.nature.com/articles/ja201711

[10]. Failoc-Rojas VE, Silva-Díaz H, Maguiña JL, Rodriguez-Morales AJ, Díaz-Velez C, Apolaya-Segura M, et al. Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru. Parasite Epidemiol Control. 2023 Aug 1;23:e00320.

[11]. Gebrezgabiher G, Yewhalaw D, Ayana M, Hailu A, Mekonnen Z. Impact of ivermectin mass drug administration on burden of soil-transmitted helminths in onchocerciasis control and elimination programs, Yeki district, southwest Ethiopia. PLoS ONE. 2022 Feb 10;17(2):e0263625.

[12]. Smit MR, Ochomo E, Aljayyoussi G, Kwambai T, Abong'o B, Bayoh N, et al. Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya. JMIR Res Protoc. 2016 Nov 17;5(4):e213.

[13]. Henriquez- Camacho C, Gotuzzo E, Echevarria J, White Jr AC, Terashima A, Samalvides F, et al. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev. 2016 Jan 18;2016(1):CD007745.

[14]. Sharun K, Shyamkumar TS, Aneesha VA, Dhama K, Pawde AM, Pal A. Current therapeutic applications and pharmacokinetic modulations of ivermectin. Vet World. 2019 Aug;12(8):1204–11.

[15]. Pharmacokinetic and pharmacodynamic considerations for treating sarcoptic mange with cross-relevance to Australian wildlife - PMC [Internet]. [cited 2024 Apr 8]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023865/

[16]. Nanoparticles for antiparasitic drug delivery - PMC [Internet]. [cited 2024 Apr 8]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882479/

[17]. Ivermectin: An Anthelmintic, an Insecticide, and Much More - PMC [Internet]. [cited 2024 Apr 8]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853155/

[18]. Golhen K, Buettcher M, Kost J, Huwyler J, Pfister M. Meeting Challenges of Pediatric Drug Delivery: The Potential of Orally Fast Disintegrating Tablets for Infants and Children. Pharmaceutics. 2023 Mar 23;15(4):1033.

[19]. Leisinger KM, Garabedian LF, Wagner AK. Improving Access to Medicines in Low and Middle Income Countries: Corporate Responsibilities in Context. South Med Rev. 2012 Dec 27;5(2):3–8.

[20]. A Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool - PMC [Internet]. [cited 2024 Apr 9]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008306/

[21]. Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, et al. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023 Jun 24;9(6):e17488.

[22]. Pion SD, Tchatchueng-Mbougua JB, Chesnais CB, Kamgno J, Gardon J, Chippaux JP, et al. Effect of a Single Standard Dose (150–200 µg/kg) of Ivermectin on Loa loa Microfilaremia: Systematic Review and Meta-analysis. Open Forum Infect Dis. 2019 Jan 11;6(4):ofz019.

[23]. Suputtamongkol Y, Premasathian N, Bhumimuang K, Waywa D, Nilganuwong S, Karuphong E, et al. Efficacy and Safety of Single and Double Doses of Ivermectin versus 7-Day High Dose Albendazole for Chronic Strongyloidiasis. PLoS Negl Trop Dis. 2011 May 10;5(5):e1044.

[24]. Impact of ivermectin administered for scabies treatment on the prevalence of head lice in Atoifi, Solomon Islands - PMC [Internet]. [cited 2024 Apr 9]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173439/

[25]. Duthaler U, Leisegang R, Karlsson MO, Krähenbühl S, Hammann F. The effect of food on the pharmacokinetics of oral ivermectin. J Antimicrob Chemother. 2020 Feb 1;75(2):438–40.

[26]. Ekoka Mbassi D, Mombo-Ngoma G, Held J, Okwu DG, Ndzebe-Ndoumba W, Kalkman LC, et al. Efficacy and safety of ivermectin for the treatment of Plasmodium falciparum infections in asymptomatic male and female Gabonese adults – a pilot randomized, double-blind, placebo-controlled single-centre phase Ib/IIa clinical trial. eBioMedicine. 2023 Nov 1;97:104814.

[27]. Jimmy B, Jose J. Patient Medication Adherence: Measures in Daily Practice. Oman Med J. 2011 May;26(3):155–9.

[28]. Kobylinski KC, Sylla M, Chapman PL, Sarr MD, Foy BD. Ivermectin Mass Drug Administration to Humans Disrupts Malaria Parasite Transmission in Senegalese Villages. Am J Trop Med Hyg. 2011 Jul 1;85(1):3–5.

[29]. Popiołek I, Piotrowicz-Wójcik K, Porebski G. Hypersensitivity Reactions in Serious Adverse Events Reported for Paracetamol in the EudraVigilance Database, 2007–2018. Pharm J Pharm Educ Pract. 2019 Jan 17;7(1):12.

[30]. González Canga A, Sahagún Prieto AM, Diez Liébana MJ, Fernández Martínez N, Sierra Vega M, García Vieitez JJ. The Pharmacokinetics and Interactions of Ivermectin in Humans—A Mini-review. AAPS J. 2008 Jan 25;10(1):42–6.

[31]. Grimsrud KN, Sherwin CMT, Constance JE, Tak C, Zuppa AF, Spigarelli MG, et al. Special population considerations and regulatory affairs for clinical research. Clin Res Regul Aff. 2015;32(2):47–56.

[32]. Barnes TM, Mijaljica D, Townley JP, Spada F, Harrison IP. Vehicles for Drug Delivery and Cosmetic Moisturizers: Review and Comparison. Pharmaceutics. 2021 Nov 26;13(12):2012.

[33]. Metta S, Khan M, Amir, Lakshmi M, Poojadevi, Shruthi K. A Review: Pharmaceutical Gels and Its Types with Prominence Role of Its Drug Delivery Systems. 2023 Jun 1;686.

[34]. Chiu S, Argaez C. Ivermectin for Parasitic Skin Infections of Scabies: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 [cited 2024 Apr 9]. (CADTH Rapid Response Reports). Available from:

http://www.ncbi.nlm.nih.gov/books/NBK545083/

[35]. Rosumeck S, Nast A, Dressler C. Ivermectin and permethrin for treating scabies. Cochrane Database Syst Rev. 2018 Apr 2;2018(4):CD012994.

[36]. Cardwell LA, Alinia H, Moradi Tuchayi S, Feldman SR. New developments in the treatment of rosacea – role of once-daily ivermectin cream. Clin Cosmet Investig Dermatol. 2016 Mar 18;9:71–7.

[37]. Manjhi PK, Sinha RI, Kumar M, Sinha KI. Comparative study of efficacy of oral ivermectin versus some topical antiscabies drugs in the treatment of scabies. J Clin Diagn Res JCDR. 2014 Sep;8(9):HC01-04.

[38]. Jia L. Nanoparticle Formulation Increases Oral Bioavailability of Poorly Soluble Drugs: Approaches Experimental Evidences and Theory. Curr Nanosci. 2005 Nov 1;1(3):237–43.

[39]. Nanoparticles in Drug Delivery: From History to Therapeutic Applications - PMC [Internet]. [cited 2024 Apr 9]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781272/

[40]. Awad H, Rawas-Qalaji M, El Hosary R, Jagal J, Ahmed IS. Formulation and optimization of ivermectin nanocrystals for enhanced topical delivery. Int J Pharm X. 2023 Dec 15;6:100210.

[41]. Gurunathan S, Kang MH, Qasim M, Kim JH. Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer. Int J Mol Sci [Internet]. 2018 Oct [cited 2024 Apr 9];19(10). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214025/

[42]. Mohammed SW, El-Megrab NA, Hasan AA, Gomaa E. A remodeled ivermectin polycaprolactone-based nanoparticles for inhalation as a promising treatment of pulmonary inflammatory diseases. Eur J Pharm Sci. 2024 Apr 1;195:106714.

[43]. Liu Y, Cheng W, Xin H, Liu R, Wang Q, Cai W, et al. Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy. Cancer Nanotechnol. 2023;14(1):28.

[44]. Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet Lond Engl. 2010 Oct 2;376(9747):1175–85.

[45]. Street SM, Christian WV. Taring the scales: Weight-of-evidence framework for biocompatibility evaluations. Regul Toxicol Pharmacol. 2024 May 1;149:105590.

[46]. Postmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada - PMC [Internet]. [cited 2024 Apr 9]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661791/

[47]. Nakhaei P, Margiana R, Bokov DO, Abdelbasset WK, Jadidi Kouhbanani MA, Varma RS, et al. Liposomes: Structure, Biomedical Applications, and Stability Parameters With Emphasis on Cholesterol. Front Bioeng Biotechnol. 2021 Sep 9;9:705886.

[48]. Zargari O, Aghazadeh N, Moeineddin F. Clinical applications of topical ivermectin in dermatology. Dermatol Online J. 2016 Sep 15;22.

[49]. Huang W, du Sert NP, Vollert J, Rice ASC. General Principles of Preclinical Study Design. Handb Exp Pharmacol. 2020 Jan 1;257:55–69.

[50]. Lee MK. Liposomes for Enhanced Bioavailability of Water-Insoluble Drugs: In Vivo Evidence and Recent Approaches. Pharmaceutics. 2020 Mar 13;12(3):264.

[51]. Subhan MA, Yalamarty SSK, Filipczak N, Parveen F, Torchilin VP. Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment. J Pers Med. 2021 Jun 18;11(6):571.

[52]. Liu P, Chen G, Zhang J. A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. Molecules. 2022 Feb 17;27(4):1372.

[53]. Fulton MD, Najahi-Missaoui W. Liposomes in Cancer Therapy: How Did We Start and Where Are We Now. Int J Mol Sci. 2023 Apr 1;24(7):6615.

[54]. Croci R, Bottaro E, Chan KWK, Watanabe S, Pezzullo M, Mastrangelo E, et al. Liposomal Systems as Nanocarriers for the Antiviral Agent Ivermectin. Int J Biomater. 2016;2016:8043983.

[55]. Bitounis D, Fanciullino R, Iliadis A, Ciccolini J. Optimizing Druggability

through Liposomal Formulations: New Approaches to an Old Concept. ISRN Pharm. 2012 Feb 9;2012:738432.

[56]. Genetu Bayih A, Debnath A, Mitre E, Huston CD, Laleu B, Leroy D, et al. Susceptibility Testing of Medically Important Parasites. Clin Microbiol Rev. 2017 Jul;30(3):647–69.

[57]. El-Boghdadly K, Pawa A, Chin KJ. Local anesthetic systemic toxicity: current perspectives. Local Reg Anesth. 2018 Aug 8;11:35–44.

[58]. Marino M, Jamal Z, Zito PM. Pharmacodynamics. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Apr 9]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK507791/

[59]. Losi S, Berra CCF, Fornengo R, Pitocco D, Biricolti G, Federici MO. The role of patient preferences in adherence to treatment in chronic disease: a narrative review. Drug Target Insights. 2021 Nov 8;15:13–20.

[60]. Boussinesq M, Enyong P, Chounna-Ndongmo P, Njouendou AJ, Pion SD, Rech A, et al. Effects of an injectable long-acting formulation of ivermectin on Onchocerca ochengi in zebu cattle. Parasite. 27:36.

[61]. Scarsi KK, Swindells S. The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data? J Int Assoc Provid AIDS Care. 2021 Apr 27;20:23259582211009011.

[62]. Lifschitz A, Virkel G, Ballent M, Sallovitz JM, Imperiale F, Pis A, et al. Ivermectin (3.15%) long-acting formulations in cattle: Absorption pattern and pharmacokinetic considerations. Vet Parasitol. 2007 Aug 1;147:303–10.

[63]. Milz R, Benson C, Knight K, Antunes J, Najarian D, Rengel PML, et al. The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia. Neuropsychiatr Dis Treat. 2023;19:531.

[64]. Intermittent Drug Dosing Intervals Guided by the Operational Multiple Dosing Half Lives for Predictable Plasma Accumulation and Fluctuation - PMC [Internet]. [cited 2024 Apr 9]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3677834/

[65]. Peterson B, Weyers M, Steenekamp JH, Steyn JD, Gouws C, Hamman JH. Drug Bioavailability Enhancing Agents of Natural Origin (Bioenhancers) that Modulate Drug Membrane Permeation and Pre-Systemic Metabolism. Pharmaceutics. 2019 Jan 16;11(1):33.

[66]. Reduction in Chronic Disease Risk and Burden in a 70-Individual Cohort Through Modification of Health Behaviors - PMC [Internet]. [cited 2024 Apr 9]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515808/

[67]. Ashour DS. Ivermectin: From theory to clinical application. Int J Antimicrob Agents. 2019 Aug 1;54(2):134–42.

[68]. VECTOR MANAGEMENT AND DELIVERY OF VECTOR CONTROL SERVICES. In: Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition [Internet]. World Health Organization; 2009 [cited 2024 Apr 9]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK143163/

[69]. Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems - PMC [Internet]. [cited 2024 Apr 9]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825503/

[70]. Pooda SH, Moiroux N, Porciani A, Courjaud AL, Roberge C, Gaudriault G, et al. Proof-of-concept study for a long-acting formulation of ivermectin injected in cattle as a complementary malaria vector control tool. Parasit Vectors. 2023 Feb 14;16:66.

[71]. Karthikeyan K, Aishwarya M, Elayaperumal S. Effectiveness of Topical 0.5% Ivermectin Shampoo in the Treatment of Pediculosis Capitis among School-going Female Children. Int J Trichology. 2022;14(2):55–9.

[72]. Zolezzi M, Abouelhassan R, Eltorki Y, Haddad PM, Noorizadeh M. Long-Acting Injectable Antipsychotics: A Systematic Review of Their Non-Systemic Adverse Effect Profile. Neuropsychiatr Dis Treat. 2021 Jun 14;17:1917–26.

[73]. Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ. Advances in Oral Drug

Delivery. Front Pharmacol. 2021 Feb 19;12:618411.

[74]. Laman M, Tavul L, Karl S, Kotty B, Kerry Z, Kumai S, et al. Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial. Lancet Infect Dis. 2022 Aug;22(8):1200–9.

[75]. Ivermectin and permethrin for treating scabies - PMC [Internet]. [cited 2024 Apr 9]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494415/

[76]. Mascarini-Serra L. Prevention of Soil-transmitted Helminth Infection. J Glob Infect Dis. 2011;3(2):175–82.

[77]. Biber A, Harmelin G, Lev D, Ram L, Shaham A, Nemet I, et al. The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 – a double-blind, randomized placebo-controlled trial. Int J Infect Dis. 2022 Sep;122:733–40.

[78]. Abd- Elsalam S, Noor RA, Badawi R, Khalaf M, Esmail ES, Soliman S, et al. Clinical study evaluating the efficacy of ivermectin in COVID- 19 treatment: A randomized controlled study. J Med Virol. 2021 Oct;93(10):5833.

[79]. Ahmad SS, Rahi M, Saroha P, Sharma A. Ivermectin as an endectocide may boost control of malaria vectors in India and contribute to elimination. Parasit Vectors. 2022 Jan 10;15:20.

[80]. Ivermectin, a potential anticancer drug derived from an antiparasitic drug - PMC [Internet]. [cited 2024 Apr 9]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505114/